Recent Quotes (30 days)

You have no recent quotes
chg | %

IntegraGen SA  

(Public, EPA:ALINT)   Watch this stock  
Find more results forALINT
4.10
0.00 (0.00%)
Delayed:   3:29pm CEST
EPA data delayed by 15 mins - Disclaimer
Currency in EUR
Range     -
52 week 3.60 - 7.00
Open     -
Vol / Avg. 0.00/198.00
Mkt cap 16.75M
P/E     -
Div/yield     -
EPS -0.57
Shares 4.09M
Beta     -
Inst. own     -
Jun 19, 2013
IntegraGen SA Mixed Shareholder Meeting - 2:00pm CEST - Add to calendar
May 16, 2013
Q4 2012 IntegraGen SA Earnings Presentation (Paris)
Apr 15, 2013
IntegraGen SA at CF&B Communication European Smallcap Event-Paris
  

Key stats and ratios

Q2 (Jun '12) 2011
Net profit margin -44.29% -43.88%
Operating margin -57.84% -53.58%
EBITD margin - -51.00%
Return on average assets -29.65% -26.94%
Return on average equity -76.86% -49.61%
Employees 25 -
Carbon Disclosure Rating - -

Address

5 rue Henri Desbrueres Genopole Campus 1 - Genavenir 8
EVRY, 91000
France
+33-1-60910900 (Phone)
+33-1-60777910 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Integragen SA is a France-based company active in the healthcare sector. It researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. It uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). It also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The Company also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.

Officers and directors

Bernard Courtieu Chairman of the Board, Chief Executive Officer
Laurence Riot Lamotte Director of Administration and Finance
Larry Yost Chief Executive Officer - IntegraGen, Inc.
Francois Liebaert Vice President - Research & Development and Medical Affairs
Emmanuel Martin Director Sales & Marketing for the Services Business Unit
Francis Rousseau Director of Genomics
Benoit Adelus Director
Philippe Boucheron Director, representing CDC Entreprises
Louis Nisbet Director, representing Kurma Life Sciences Partners
Chantal Parpex Director, representing CDC Innovation
Age: 64